Medicare Enrolled
Dr. John Vanderzyl, MD
Family Medicine · Sugar Land, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Vanderzyl from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vanderzyl? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vanderzyl
Dr. John Vanderzyl is a family medicine in Sugar Land, TX, with 19 years in practice. Based on federal Medicare data, Dr. Vanderzyl performed 4,562 Medicare services across 3,682 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vanderzyl received a total of $18,589 from 78 pharmaceutical and/or device companies across 943 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vanderzyl is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 4% volume in TX$ $18,589 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,562
Medicare services
Top 4% in TX for family medicine
3,682
Unique beneficiaries
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~240 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) | 1,369 | $56 | $135 |
| Office visit, established patient (30-39 min) | 720 | $84 | $160 |
| Annual wellness visit, follow-up | 607 | $124 | $250 |
| Electrocardiogram (EKG), 12-lead | 323 | $8 | $80 |
| Annual depression screening | 221 | $17 | $25 |
| Automated urinalysis | 193 | $2 | $20 |
| Drug injection, under skin or into muscle | 182 | $10 | $30 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 126 | $158 | $250 |
| Bone density scan (DEXA) | 106 | $36 | $200 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 96 | $8 | $30 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | 90 | $55 | $160 |
| Injection, methylprednisolone acetate, 80 mg | 78 | $8 | $40 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 70 | $158 | $250 |
| Removal of impacted ear wax | 57 | $28 | $75 |
| Transitional care management services for problem of at least moderate complexity | 46 | $156 | $240 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 34 | $35 | $140 |
| Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | 31 | $6 | $80 |
| New patient office visit (30-44 min) | 30 | $59 | $170 |
| Blood glucose (sugar) level | 29 | $4 | $30 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 27 | $16 | $45 |
| Injection, ketorolac tromethamine, per 15 mg | 18 | $0 | $30 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $1 | $20 |
| New patient office visit (45-59 min) | 17 | $103 | $210 |
| Office visit, established patient (10-19 min) | 17 | $39 | $79 |
| Transitional care management services for problem of high complexity | 16 | $207 | $300 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 15 | $31 | $95 |
| Retinal photography (fundus photo) | 14 | $14 | $100 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 12 | $40 | $135 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$18,589
Total received (2018-2024)
Avg $2,656/year across 7 years
Top 1% in TX for family medicine
78
Companies
943
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,578 (99.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,189
2023$2,851
2022$2,399
2021$2,911
2020$1,987
2019$2,421
2018$2,831
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$1,993
Abbott Laboratories
$1,616
Amgen Inc.
$1,284
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,278
Lilly USA, LLC
$986
AstraZeneca Pharmaceuticals LP
$904
Teva Pharmaceuticals USA, Inc.
$882
GlaxoSmithKline, LLC.
$858
PFIZER INC.
$622
AbbVie Inc.
$606
Janssen Pharmaceuticals, Inc
$575
Amarin Pharma Inc.
$523
OptiNose US, Inc.
$479
SANOFI-AVENTIS U.S. LLC
$442
Takeda Pharmaceuticals U.S.A., Inc.
$375
Bayer HealthCare Pharmaceuticals Inc.
$337
Astellas Pharma US Inc
$333
Merck Sharp & Dohme Corporation
$311
Bayer Healthcare Pharmaceuticals Inc.
$300
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$275
Inspire Medical Systems, Inc.
$259
ABBVIE INC.
$234
Bausch Health US, LLC
$230
Eisai Inc.
$191
Amneal Pharmaceuticals LLC
$181
Shire North American Group Inc
$181
Optinose US, Inc.
$176
Boston Scientific Corporation
$158
Corcept Therapeutics
$145
Saluda Medical Americas, Inc.
$115
Mannkind Corporation
$110
Allergan, Inc.
$90
Merck Sharp & Dohme LLC
$89
SHIELD THERAPEUTICS INC
$85
Genentech USA, Inc.
$82
AbbVie, Inc.
$82
Biohaven Pharmaceuticals, Inc.
$82
SANOFI PASTEUR INC.
$77
Esperion Therapeutics, Inc.
$73
Exact Sciences Corporation
$59
Clarus Therapeutics Inc.
$59
Radius Health, Inc.
$51
Sumitomo Pharma America, Inc.
$49
Ironshore Pharmaceuticals Inc.
$42
Shield Therapeutics Inc
$38
Biohaven Pharmaceutical Holding Company Ltd.
$32
Hologic, LLC
$32
Althera Pharmaceuticals LLC
$32
Antares Pharma, Inc.
$31
Verity Pharmaceuticals Inc.
$31
Corium, LLC
$30
Gemini Laboratories, LLC
$27
IDORSIA PHARMACEUTICALS US INC
$27
Phathom Pharmaceuticals, Inc.
$26
Orexigen Therapeutics, Inc.
$26
Azurity Pharmaceuticals, Inc.
$24
ARBOR PHARMACEUTICALS, INC.
$24
Kowa Pharmaceuticals America, Inc.
$22
Seqirus USA Inc
$21
Medtronic, Inc.
$20
Tris Pharma Inc
$19
Axsome Therapeutics, Inc.
$19
Dexcom, Inc.
$18
Horizon Therapeutics plc
$17
Dynavax Technologies Corporation
$17
Mylan Specialty L.P.
$16
EISAI INC.
$15
DERMIRA, INC.
$15
Paratek Pharmaceuticals, Inc.
$14
Medline Industries, Inc.
$14
Phadia US Inc.
$14
E.R. Squibb & Sons, L.L.C.
$14
Mission Pharmacal Company
$13
Adlon Therapeutics L.P.
$13
Nuvectra Corporation
$13
Ironwood Pharmaceuticals, Inc
$12
Nalpropion Pharmaceuticals, Inc.
$12
AMAG Pharmaceuticals, Inc.
$11
Top 3 companies account for 26.3% of total payments
Associated products mentioned in payments ›
AC2 · ACCRUFER · ADACEL · ADHANSIA XR · ADVAIR · AFREZZA · AIRSUPRA · AJOVY · ANORO · ANORO ELLIPTA · APLENZIN · AREXVY · AUSTEDO · AZSTARYS · Aimovig · AirDuo Digihaler · Algovita · Androgel · Auvelity · BEXSERO · BREO · BREZTRI · BYDUREON · CARDIOMEMS · CHANTIX · CINQAIR · COLOGUARD · COMIRNATY · CONTRAVE · CREON · CardioMEMS HF System · Cologuard Collection Kit · Confirm Rx · DUZALLO · Dayvigo · Dexcom G6 Transmitter · Dexilant · Dyanavel XR · EDARBI · ELIQUIS · EMGALITY · ETERNA · EVENITY · EVUSHELD · Edarbyclor · Evoke · FARXIGA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · FLUZONE HIGH-DOSE · FLUZONE QUADRIVALENT · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · Ferralet · Fluad · FreeStyle Libre · GARDASIL · GARDASIL 9 · GEMTESA · HUMIRA · Heplisav-B · INSPIRE · INTRAROSA · INVOKANA · ImmunoCAP · Inspire Upper Airway Stimulation System · JANUVIA · JARDIANCE · JATENZO · Jornay PM 20mg capsules (Bottle of 100) · KRYSTEXXA · Kerendia · Korlym · LINZESS · LYRICA · Livalo · M-M-R II · MOTEGRITY · MOUNJARO · MYDAYIS · MYRBETRIQ · NEXLETOL · NOCDURNA · NURTEC ODT · NUZYRA · OTREXUP · Otezla · Otovel · Ozempic · PNEUMOVAX 23 · PREMARIN · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · PROCLAIM · PRODIGY · Proclaim IPG · Prolia · QBREXZA · QULIPTA · QUVIVIQ · QVAR · ROTATEQ · RYBELSUS · Repatha · Roszet · Rybelsus · SHINGRIX · SOLIQUA · SOLIQUA 100/33 · STEGLATRO · STIOLTO RESPIMAT · SYNTHROID · Saxenda · Synthroid · TOUJEO · TRADJENTA · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · ThinPrep · Tlando · Trintellix · Truly Ouchless FLU Bandages Display · Tymlos · UBRELVY · UNITHROID · VOQUEZNA · VRAYLAR · VYVANSE · Vascepa · VenaSeal · Veozah · Victoza · WATCHMAN · WELLBUTRIN · Wegovy · XARELTO · XIFAXAN · Xhance · Xofluza · Xultophy 100/3.6 · Yupelri
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 1% for family medicine in TX.
Equivalent to $407 per 100 Medicare services performed
Geographic Context
Family Medicines within 10 mi
1,306
Per 100K population
151.9
County median income
$113,409
Nearest hospital
HOUSTON METHODIST SUGARLAND HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Vanderzyl is a clinical cardiology specialist, with above-average Medicare volume (top 4% in TX), and high industry engagement (low-engagement, top 1%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Vanderzyl experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Vanderzyl performed 1,369 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vanderzyl receive payments from pharmaceutical companies?
Yes. Dr. Vanderzyl received a total of $18,589 from 78 companies across 943 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vanderzyl's costs compare to other family medicines in Sugar Land?
Dr. Vanderzyl's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vanderzyl) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicines in Sugar Land
Browse family medicines in Sugar Land ranked by procedure volume and transparency data.
Highest volume
Top Family Medicines in TX
Family Medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicines in TX
Which TX family medicines receive the most from drug and device companies.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology